On October 6, 2026 Orion Corporation ("Orion Pharma") and Qilu Pharma Europe ("Qilu") reported to have entered into an agreement to commercialise intravenous (IV) pembrolizumab biosimilar in Europe. Pembrolizumab is an immune checkpoint inhibitor which is used to treat various cancers. Qilu is currently developing IV pembrolizumab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Orion Pharma will gain exclusive right to distribute, market and sell Qilu’s IV pembrolizumab biosimilar in Europe. Qilu will supply the product to Orion Pharma, and is entitled to receive a share of profits from Orion Pharma as well as certain development, regulatory and sales milestone payments.

"We are pleased to expand our strategic partnership with Qilu," said Satu Ahomäki, EVP Generics and Consumer Health, Orion Pharma. "With this agreement, we are one step closer to reaching our division’s long-term targets and strategic goals, and to creating broader access to affordable quality medicines."

(Press release, Orion, OCT 6, 2026, View Source [SID1234673247])